(Total Views: 413)
Posted On: 02/14/2023 8:50:49 AM
Post# of 36541
What I am still wondering is the significantly value that GNBT should have related to its share in
Olaregen - in the May CC we were told that they have the capability to generate double digit million dollar revenues from Excellagen within 6 months of the launch that they had laid out detailed plans for, and
Oral-lyn - it is a stage III clinical trial product that was - according to Ana Gluskin (back in the days) - considered to have a potential to generate at least 100s of millions of dollars in revenues once it is FDA approved.
In my view, it is IMPOSSIBLE, that these two mentioned properties of GNBT now have to be considered worthless. To the contrary, they definitely HAVE SIGNIFICANT value, and they should at least be sold for the benefit of us shareholders.
Is this too optmistic thinking? If yes, where is the flaw in my thinking??
Olaregen - in the May CC we were told that they have the capability to generate double digit million dollar revenues from Excellagen within 6 months of the launch that they had laid out detailed plans for, and
Oral-lyn - it is a stage III clinical trial product that was - according to Ana Gluskin (back in the days) - considered to have a potential to generate at least 100s of millions of dollars in revenues once it is FDA approved.
In my view, it is IMPOSSIBLE, that these two mentioned properties of GNBT now have to be considered worthless. To the contrary, they definitely HAVE SIGNIFICANT value, and they should at least be sold for the benefit of us shareholders.
Is this too optmistic thinking? If yes, where is the flaw in my thinking??
(2)
(0)Scroll down for more posts ▼
